GEOVAX LABS, INC. (GOVX) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of GEOVAX LABS, INC. $0.54, price $0.32, upside +68.7%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch GEOVAX LABS, INC. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.3201 – $2,284 · fair‑value band $0.3500 – $0.6700 · the $0.3201 price screens below the $0.5400 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow GEOVAX LABS in your weekly email
Every Wednesday you see whether GEOVAX LABS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
Show more
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Stock analysis
GEOVAX LABS, INC. (GOVX) currently trades at $0.3201, while our model-based Fair Value estimate is $0.5400, implying the stock looks roughly 40.7% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.3500 (bear) to $0.6700 (bull), the price of $0.3201 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
GEOVAX LABS, INC. reported revenue of $2.5M in FY2025 versus $385K in FY2021, a compound +59.5%/yr. Reported net income was −$21.5M in FY2025.
Key figures
Market cap $3.7M · EPS (TTM) $−5.59 · Return on equity −892% · Return on assets (EBIT) −228% · Free cash flow −$21.5M · Net cash $2.2M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 98% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 69%, GOVX screens cheaper than that median.
Fair Value models
Bear $0.3500Fair Value $0.5400Bull $0.6700
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.12/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−37.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+213.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Start year 2020 (pandemic). Over 10 years: +19.2% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−154.5% (2020) → −869.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "GEOVAX LABS, INC. Fair Value". https://www.fairvalue-calculator.com/stock/GOVX
Frequently asked questions
Is GEOVAX LABS, INC. (GOVX) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.5400 versus a price of $0.3201, about +69% upside (undervalued).
What is the fair value of GOVX?
Our model-based fair value for GEOVAX LABS, INC. is $0.5400 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.3201.
What is the quality score of GOVX?
GEOVAX LABS, INC. has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GEOVAX LABS, INC. (GOVX)?
Our model-based price target is the fair value of $0.5400 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario $0.3500, optimistic scenario $0.6700. It is a calculation from audited fundamentals, not an analyst target.
What is the GEOVAX LABS, INC. stock forecast for 2026?
Our models put fair value at $0.5400, about +69% upside versus a price of $0.3201 (undervalued). Cautious scenario $0.3500, optimistic scenario $0.6700. The calculation is refreshed regularly with new filings.
What is the intrinsic value of GEOVAX LABS, INC. (GOVX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GEOVAX LABS, INC. it is $0.5400 per share (as of Sep 27, 2026), against a price of $0.3201. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is GEOVAX LABS, INC. stock overvalued or undervalued in 2026?
As of Sep 27, 2026, GOVX trades below its calculated fair value: price $0.3201, fair value $0.5400, a gap of about +69% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GOVX?
No. The price is what the market pays today ($0.3201); the fair value is what the company's own numbers justify ($0.5400). For GEOVAX LABS, INC. the two are $0.2199 per share apart. That gap is exactly why we show both numbers side by side.
How much is GEOVAX LABS, INC. worth?
The market values GEOVAX LABS, INC. at about $3.7M (market capitalisation, as of Sep 27, 2026). Per share that is $0.3201; our models calculate a fair value of $0.5400 per share.
What do the bullish and bearish scenarios say about GOVX?
Our models span a range for GEOVAX LABS, INC.: cautious scenario $0.3500, base $0.5400, optimistic $0.6700 per share (as of Sep 27, 2026, price $0.3201). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of GEOVAX LABS, INC. (GOVX)?
Balance-sheet figures for GEOVAX LABS, INC. (as of Sep 27, 2026): debt of 0.00 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is GOVX from its 52-week high?
GEOVAX LABS, INC. trades at $0.3201, about 98% below its 52-week high of $15.11 and at the low of $0.3201 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5400 is for.
Which stocks are comparable to GEOVAX LABS, INC.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GEOVAX LABS, INC. stock attractive at the current price?
The data as of Sep 27, 2026: price $0.3201, calculated fair value $0.5400 (+69%), Quality Score 52/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GOVX calculated?
We run GEOVAX LABS, INC. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.5400, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. GEOVAX LABS, INC. currently trades 41 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GEOVAX LABS, INC. (GOVX)?
The closing price on Oct 2, 2026 was $0.3201. Our model-based fair value is $0.5400, about +69% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GEOVAX LABS, INC. right now?
The price is below even our cautious bear case ($0.3500). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($0.3500 to $0.6700) leaves room in how you read the outcome.
Key figures of GEOVAX LABS, INC.
How large is the market capitalisation of GEOVAX LABS, INC. (GOVX)?
The market capitalisation of GEOVAX LABS, INC. is $3.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of GEOVAX LABS, INC. (GOVX)?
Earnings per share at GEOVAX LABS, INC. are $−5.59. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of GEOVAX LABS, INC. (GOVX)?
The return on equity (ROE) of GEOVAX LABS, INC. is −892% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GEOVAX LABS, INC. (GOVX)?
On an EBIT basis the return on assets of GEOVAX LABS, INC. is −228% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does GEOVAX LABS, INC. (GOVX) generate?
The free cash flow of GEOVAX LABS, INC. is −$21.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does GEOVAX LABS, INC. (GOVX) hold?
GEOVAX LABS, INC. holds more cash than debt, $2.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch GEOVAX LABS, INC. in the live analysis
One click puts GEOVAX LABS, INC. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026